Document is current
Any future updates will be listed below
-
Authors
Hill, Colin S.
Rosati, Lauren M.
Hu, Chen
Fu, Wei
Sehgal, Shuchi
Hacker-Prietz, Amy
Wolfgang, Christopher L.
Weiss, Matthew J.
Burkhart, Richard A.
Hruban, Ralph H.
De Jesus-Acosta, Ana
Le, Dung T.
Zheng, Lei
Laheru, Daniel A.
He, Jin
Narang, Amol K.
Herman, Joseph M.
-
Funding
Funding for this research was provided by:
Skip Viragh Center for Pancreatic Cancer Research and Clinical Care
- License Information
-
More Information
Article History
Received: 22 April 2021
Accepted: 15 November 2021
First Online: 7 February 2022
Disclosure
: Chen Hu received personal fees from Merck & Co. Dung Le serves on advisory boards for Merck, Bristol Myers Squibb, and Janssen and has received research funding from Merck, Bristol Myers Squibb, Aduro Biotech, Curegenix, Medivir, and Nouscom. She has received speaking honoraria from Merck and is an inventor of licensed intellectual property related to technology for mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. The terms of these arrangements are being managed by Johns Hopkins. Joseph Herman has research funding from the Canopy Cancer Collective and has been a consultant for Boston Scientific.
